Performance of intraoperative AI-assisted Label-Free Stimulated Raman Histology in Recurrent Brain Tumors

Clicks: 5
ID: 338015
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #144 of 144 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 144 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Therapy-induced tissue alterations complicate intraoperative diagnosis of recurrent CNS tumors. We evaluated stimulated Raman histology (SRH) combined with convolutional neural networks (CNNs) for rapid tumor detection and classification. Methods In this bicentric observational study, fresh tissue from patients undergoing resection or stereotactic biopsy for suspected recurrent CNS tumors was imaged with fiber-laser-based SRH. CNN1 performed binary tumor/non-tumor prediction and CNN2 histotype classification. CNN1 was evaluated against blinded neuropathologist SRH consensus and CNN2 against the final integrated histopathological diagnosis. Results Of 382 acquired SRH images, 262 images from 143 patients were included. CNN1 achieved an AUC of 0.975 (95% CI, 0.95–1.00) for tumor detection. An exploratory cohort-derived tumor probability threshold of ≥ 59 increased specificity from 70.7% to 92.0% while maintaining 95.2% sensitivity and identifying 71.4% of radiation necrosis samples. Among 212 images in treatment subgroup analysis, CNN1 accuracy did not differ significantly across prior-treatment groups (overall 90.1%; p = 0.080). CNN2 accuracy declined from 61.8% after surgery alone to 39.0% after surgery, radiotherapy, and medical treatment (χ²=6.04, p = 0.049). Multimodal therapy was independently associated with lower odds of correct CNN2 prediction (adjusted OR, 0.10 [95% CI, 0.02–0.39]; p = 0.001 and 0.04 [95% CI, 0.01–0.20]; p < 0.001). 120/382 images (31.5%) were of insufficient diagnostic quality; application of the quality control threshold would have rejected 84/120 (70.0%). Conclusions CNN1 maintained high tumor/non-tumor discrimination across treatment subgroups when image quality was sufficient, whereas CNN2 entity-classification performance declined with increasing treatment intensity. Reliable SRH-based diagnosis in recurrent tumors requires validated image-quality control measures and model adaptation to recurrent disease.
Reference Key
openalex_W7224736052 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gina Fürtjes, Abdulkader Al Shughri, Thomas Stehlé, David Reinecke, Anna-Katharina Meißner, Nina Jung, Zeynep Mercan, Nicolas Noel Neidert, Pierre Scheffler, Lili Leyer, Claire Wang, Zachari Gueorguiev, Niklas von Spreckelsen, Daniel F. Ruess, Christian W. Freudiger, Florian Khalid, Adrian Ion‐Mărgineanu, Roland Goldbrunner, Jürgen Beck, Volker Neuschmelting, Jakob Straehle
Are you one of these authors? Claim your profile
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag267
URL
https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdag267/72608742/vdag267.pdf
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.